FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Diltiazem Hydrochloride Injection
Status: Currently in Shortage
»Date first posted: 02/21/2018
»Therapeutic Categories: Cardiovascular

Expand all

Akorn Pharmaceuticals (Revised 04/08/2022)

Company Contact Information:
800-932-5676

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Diltiazem HCl Injection 5 mg / mL, 10 mL, 10 vials (NDC 17478-0937-10) On allocation, then discontinued. Discontinuation of the manufacture of the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 1 vial (NDC 17478-0937-25) Discontinued Discontinuation of the manufacture of the drug
Diltiazem HCl Injection 5 mg / mL, 25 mL, 10 vials (NDC 17478-0937-26) Discontinued Discontinuation of the manufacture of the drug
Diltiazem HCl Injection 5 mg / mL, 5 mL, 10 vials (NDC 17478-0937-05) Discontinued Discontinuation of the manufacture of the drug

Athenex Pharmaceutical Division, LLC (Athenex) (Reverified 05/20/2022)

Company Contact Information:
855-273-0154

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
25 mg/5mL vial (NDC 70860-301-05) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
50 mg/10mL vial (NDC 70860-301-10) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154
125 mg/25mL vial (NDC 70860-301-25) Available Marketed by Athenex. To order, contact Athenex at 855-273-0154

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 04/08/2022)

Company Contact Information:
800-631-2174

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
5 mg/mL, 5 mL vial (NDC 0641-6013-10) Inventory is currently available. Additional lots will be scheduled for manufacturing. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 10 mL vial (NDC 0641-6014-10) Inventory is currently available Additional lots are scheduled for manufacturing. Product will be made available as it is released. Demand increase for the drug
5 mg/mL, 30 mL vial (NDC 0641-6015-10) This presentation is temporarily on backorder. Additional lots are scheduled for manufacturing and will be available in the April 2022 timeframe. Product will be made available as it is released. Demand increase for the drug

Hospira, Inc. (Revised 05/10/2022)

Company Contact Information:
844-646-4398

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
100 mg; Single Dose ADD-Vantage Vial (NDC 00409-4350-03) Limited Supply Available. Next Delivery: May 2022; Estimated Recovery: November 2022 Check Wholesaler for Availability Shortage per Manufacturer: Manufacturing Delay Other
50 mg/10 mL (5 mg/mL); Single Dose Glass Fliptop Vial (NDC 00409-1171-02) Discontinued Discontinuation of the manufacture of the drug

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English